South Korean diagnostics company NGeneBio Co. is accelerating its expansion into the ASEAN precision diagnosis market.

Breast and ovarian cancer precision diagnosis product - BRCAccuTest PLUS of NGeneBio has completed the evaluation and started clinical next-generation sequencing (NGS) tests at Ho Chi Minh City Oncology Hospital in Vietnam. K-Hospital (National Cancer Centre) is also going to start the clinical NGS tests as soon as the evaluation is completed. 

BRCAccuTest PLUS which was highly evaluated at the local clinical site in Vietnam and has the advantages of Registered CE-IVD for the first time in Asia,  detected BRCA1/2 gene mutations at once, provided optimal and personalised treatment methods to patients through NGS diagnosis and genetic testing. It is designed to apply and automatically analyse the NGS data produced from test reagents and issue a clinical report.

In addition, the largest national and public hospital Bach Mai in Vietnam is currently discussing to use BRCAccuTest PLUS in the clinical test of PARPi-targeted therapy for expanding the prescription for prostate cancer patients.

Following the start of clinical NGS test in Vietnam, it is not only easier for the company to supply products to the national and public hospitals through public bidding, but also to expand the use of products in individual and private hospitals.